Last reviewed · How we verify
Humira
At a glance
| Generic name | Humira |
|---|---|
| Also known as | Cosentyx, IL 12B genetic polymorphism (rs3213094), adalimumab, Adalimumab |
| Sponsor | Sohag University |
| Target | Tumor necrosis factor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Ankylosing spondylitis
- Axial spondyloarthritis
- Behcet's disease
- Crohn's disease
- Hidradenitis suppurativa
- Juvenile idiopathic arthritis
- Non-infectious anterior uveitis
- Non-infectious intermediate, posterior and panuveitis
- Plaque psoriasis
- Psoriasis with arthropathy
- Psoriatic arthritis
- Pustular psoriasis
- Pyoderma gangrenosum
- Rheumatoid arthritis
- Ulcerative colitis
Common side effects
- Injection site reactions
- Infections (upper respiratory, sinusitis)
- Headache
- Rash
Serious adverse events
- Serious infections
- Pneumonia
- Active tuberculosis
- Serious opportunistic infections
- Septic arthritis
- Cellulitis
- Diverticulitis
- Pyelonephritis
- Lupus-like syndrome
- Positive ANA titers
Key clinical trials
- Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
- Subconjunctival Humira for Boston Keratoprosthesis (PHASE1)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases (PHASE1, PHASE2)
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- Preventing Structural Damage in Early Psoriatic Arthritis (PHASE4)
- A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |